Cargando…

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy

INTRODUCTION: In early-stage HER2 positive breast cancer (BC) patients, tumor response to neoadjuvant chemotherapy (NACT) predict survival outcomes. Patients achieving less than pathological complete response (pCR) have a worse prognosis, however, this group is heterogeneous. Nowadays limited data o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omarini, Claudia, Bettelli, Stefania, Manfredini, Samantha, Barbolini, Monica, Isca, Chrystel, Cortesi, Giulia, Maiorana, Antonino, Tazzioli, Giovanni, Dominici, Massimo, Piacentini, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2020
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264751/ https://www.ncbi.nlm.nih.gov/pubmed/32485588 http://dx.doi.org/10.1016/j.tranon.2020.100794

Ejemplares similares

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
por: Isca, Chrystel, et al.
Publicado: (2021)

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
por: Omarini, Claudia, et al.
Publicado: (2020)

Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2019)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
por: Omarini, Claudia, et al.
Publicado: (2022)

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
por: Omarini, Claudia, et al.
Publicado: (2018)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review
por: Canino, Fabio, et al.
Publicado: (2022)

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
por: Omarini, Claudia, et al.
Publicado: (2018)

Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study
por: Aramini, Beatrice, et al.
Publicado: (2020)

Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era
por: Toss, A., et al.
Publicado: (2021)

Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer
por: Reggiani Bonetti, Luca, et al.
Publicado: (2018)

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
por: Cerma, Krisida, et al.
Publicado: (2023)

Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study
por: Toss, Angela, et al.
Publicado: (2021)

Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications
por: Toss, Angela, et al.
Publicado: (2018)

Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study
por: Isca, Chrystel, et al.
Publicado: (2022)

The Role of Exosomes in Breast Cancer Diagnosis
por: Piombino, Claudia, et al.
Publicado: (2021)

Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!
por: Omarini, Claudia, et al.
Publicado: (2020)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
por: Ibragimova, M. K., et al.
Publicado: (2023)

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations
por: Guaitoli, Giorgia, et al.
Publicado: (2021)

Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence
por: Aramini, Beatrice, et al.
Publicado: (2022)

GD2 expression in breast cancer
por: Orsi, Giulia, et al.
Publicado: (2017)

Expression of ALDH and SOX-2 in Pulmonary Sclerosing Pnemocytoma (PSP) of the Lung: Is There a Meaning Behind?
por: Aramini, Beatrice, et al.
Publicado: (2020)

ALDH Expression in Angiosarcoma of the Lung: A Potential Marker of Aggressiveness?
por: Aramini, Beatrice, et al.
Publicado: (2020)

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
por: Viansone, A., et al.
Publicado: (2022)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
por: Mizuno, Takaaki, et al.
Publicado: (2020)

New Perspectives in Different Gene Expression Profiles for Early and Locally Advanced Non-Small Cell Lung Cancer Stem Cells
por: Masciale, Valentina, et al.
Publicado: (2021)

Personalized Systemic Therapies in Hereditary Cancer Syndromes
por: Mastrodomenico, Luciana, et al.
Publicado: (2023)

Cancer stem cells and macrophages: molecular connections and future perspectives against cancer
por: Aramini, Beatrice, et al.
Publicado: (2021)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
por: Arai, Roberto J., et al.
Publicado: (2018)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
por: Ma, Youzhao, et al.
Publicado: (2023)

Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study
por: Masciale, Valentina, et al.
Publicado: (2019)

CD44+/EPCAM+ cells detect a subpopulation of ALDH(high) cells in human non-small cell lung cancer: A chance for targeting cancer stem cells?
por: Masciale, Valentina, et al.
Publicado: (2020)

The Influence of Cancer Stem Cells on the Risk of Relapse in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Prospective Cohort Study
por: Masciale, Valentina, et al.
Publicado: (2022)

Cancer Stem Cells and Cell Cycle Genes as Independent Predictors of Relapse in Non-small Cell Lung Cancer: Secondary Analysis of a Prospective Study
por: Masciale, Valentina, et al.
Publicado: (2022)

Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma
por: Maur, Michela, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_eta9llkmmsnf1665d9udm02aj6